Inventiva S.A.·Healthcare

Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first quarter of 2026, including its cash, cash equivalents and revenues.

Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain will present at at the upcoming 2026 Jefferies Global Healthcare Conference. The conference is being held June 2-4, 2026, in New York City.

Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA's balance sheet has sufficient financing to reach that readout. But please bear in mind that it's a binary outcome.

Daix (France), New York City (New York, United States) , May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona.

Daix (France), New York City (New York, United States), May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona.

Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 - Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique spécialisée dans le développement de thérapies par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui la présentation de deux abstracts lors du prochain congrès annuel de l'European Association for the Study of the Liver, EASL Congress 2026, qui se tiendra du 27 au 30 mai 2026 à Barcelone.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Healthcare
Biotechnology
114
2020-07-10
0.88